Intrinsic Value of S&P & Nasdaq Contact Us
← All Scored Tickers
Ultragenyx Pharmaceutical Inc. RARE
SharesGrow 7-Criteria Evaluation
56/100
SharesGrow Score
3/7 criteria passed
VALUE Pass
Is the stock reasonably priced for its earnings and growth?
How we measure: Composite of trailing P/E vs S&P avg (20%), forward PEG (35%), price target upside — how far below analyst target (25%), and trailing PEG (20%). Trading far below target = high score. Composite ≥ 60 = Pass.
FUTURE Pass
Are analysts forecasting strong future growth?
How we measure: Primarily based on analyst consensus. ≥ 70% buy ratings = Pass (unless target implies > 15% downside). 50-70% = Partial. Price target upside is a bonus, not a requirement.
PAST Fail
Has the company been consistently profitable?
How we measure: Checks profitability in each of the last 4 fiscal years. Pass = profitable all 4 years.
0/4 yrs
Profitable yrs
$-5.83
EPS
~
HEALTH Partial
Is the balance sheet strong and debt manageable?
How we measure: Evaluates debt-to-equity (< 0.5 ideal), current ratio (> 1.5 ideal), and interest coverage (> 8x ideal).
~
MOAT Partial
Does the company have a durable competitive advantage?
How we measure: Composite score: gross margin level (35%) + gross margin trend (15%) + market cap size (30%) + revenue size (20%). Score ≥ 70 = Pass.
55/100
Moat score
83.8%
Gross margin
-8.4pp
GM trend
$2.4B
Market cap
GROWTH Pass
Is the company growing revenue and earnings consistently?
How we measure: Average annual revenue growth and net income growth over the last 3–4 years. Both must exceed 5%/yr for Pass.
+22.9%/yr
Avg rev growth
+6.5%/yr
Avg NI growth
INCOME Fail
Is the company generating strong profit margins?
How we measure: Net profit margin of the latest fiscal year. ≥ 15% = Pass, > 0% = Partial, negative = Fail.
-85.4%
Net margin
$673M
Revenue

Score last updated: 2026-04-15 05:16:12

Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message